33.60

0.51% 0.17

Gsk Plc Adr (GSK)

Overview News Price History Option Chain Discussions Forecast Stock Split Dividend History

Gsk Plc Adr stock is traded at $33.60, with a volume of 6.72M. It is up +0.51% in the last 24 hours and up +0.75% over the past month. In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, antiviral, and vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Previous Close:

$33.43

Open:

$33.135

24h Volume:

6.72M

Relative Volume:

1.17

Market Cap:

$68.55B

Revenue:

$39.71B

Net Income/Loss:

$3.17B

P/E Ratio:

9.7609

EPS:

3.4423

Net Cash Flow:

$6.05B

1W Performance:

-1.03%

1M Performance:

+0.75%

6M Performance:

-17.57%

1Y Performance:

-7.16%

1-Day Range:

$33.04

$33.87

1-Week Range:

$33.04

$34.55

52-Week Range:

$32.83

$45.92

Gsk Plc Adr Stock (GSK) Company Profile

Name

Gsk Plc Adr

Sector

Healthcare (1176)

Industry

Drug Manufacturers - General (18)

Phone

Address

Employee

70,200

Twitter

@GSK

Next Earnings Date

2024-10-30

Latest SEC Filings

GSK's Discussions on Twitter

Compare GSK with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GSK Gsk Plc Adr	33.60	68.55B	39.71B	3.17B	6.05B	1.5382
LLY Lilly Eli Co	767.76	690.46B	40.86B	8.37B	-2.28B	9.25
NVO Novo Nordisk Adr	85.00	377.54B	39.36B	13.79B	9.83B	3.086
JNJ Johnson Johnson	144.47	347.83B	87.70B	14.68B	19.03B	6.05
ABBV Abbvie Inc	175.58	310.27B	55.53B	5.12B	15.62B	2.88
MRK Merck Co Inc	98.05	248.03B	63.17B	12.15B	14.84B	4.77

Gsk Plc Adr Stock (GSK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-15-24	Downgrade	Deutsche Bank	Buy → Hold
Nov-12-24	Downgrade	Jefferies	Buy → Hold
Oct-31-24	Downgrade	Guggenheim	Buy → Neutral
Jul-08-24	Downgrade	UBS	Buy → Neutral
May-30-24	Initiated	Goldman	Neutral
Mar-04-24	Upgrade	Guggenheim	Neutral → Buy
Feb-13-24	Upgrade	Citigroup	Neutral → Buy
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight
Jan-16-24	Resumed	UBS	Buy
Jan-03-24	Upgrade	Jefferies	Hold → Buy
Jul-14-23	Initiated	HSBC Securities	Reduce
Mar-17-23	Upgrade	Deutsche Bank	Hold → Buy
Feb-27-23	Resumed	Goldman	Buy
Jan-03-23	Downgrade	JP Morgan	Neutral → Underweight
Dec-05-22	Downgrade	BofA Securities	Neutral → Underperform
Nov-11-22	Downgrade	UBS	Neutral → Sell
Sep-15-22	Upgrade	Credit Suisse	Underperform → Neutral
Sep-08-22	Downgrade	Jefferies	Buy → Hold
Aug-05-22	Resumed	Morgan Stanley	Equal-Weight
Jul-21-22	Resumed	Citigroup	Neutral
Feb-11-22	Downgrade	DZ Bank	Buy → Hold
Nov-05-21	Upgrade	Barclays	Underweight → Equal Weight
Jun-24-21	Upgrade	Deutsche Bank	Sell → Hold
Mar-23-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Feb-04-21	Downgrade	Deutsche Bank	Hold → Sell
Jan-20-21	Downgrade	Credit Suisse	Neutral → Underperform
Jan-15-21	Initiated	Deutsche Bank	Hold
Nov-02-20	Upgrade	Liberum	Hold → Buy
Sep-29-20	Initiated	Berenberg	Buy
Feb-12-20	Downgrade	Shore Capital	Hold → Sell
Jan-16-20	Downgrade	Barclays	Equal Weight → Underweight
Dec-02-19	Initiated	SVB Leerink	Outperform
Nov-21-19	Upgrade	UBS	Neutral → Buy
Oct-11-19	Upgrade	Cantor Fitzgerald	Hold → Buy
Sep-03-19	Resumed	Citigroup	Neutral
Sep-03-19	Upgrade	Societe Generale	Sell → Buy
Aug-13-19	Resumed	JP Morgan	Neutral
Jun-17-19	Resumed	Morgan Stanley	Underweight
Mar-08-19	Downgrade	Shore Capital	Buy → Hold
Feb-22-19	Downgrade	UBS	Buy → Neutral
Jan-14-19	Downgrade	Exane BNP Paribas	Outperform → Neutral
Dec-11-18	Resumed	Jefferies	Buy
Oct-09-18	Initiated	Guggenheim	Neutral
Aug-30-18	Downgrade	Liberum	Buy → Hold
Apr-04-18	Upgrade	Exane BNP Paribas	Neutral → Outperform
Mar-22-18	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Feb-09-18	Upgrade	Kepler	Reduce → Hold